| pubmed-article:20644086 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C0023487 | lld:lifeskim |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C0052416 | lld:lifeskim |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C1511726 | lld:lifeskim |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:20644086 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
| pubmed-article:20644086 | pubmed:issue | 24 | lld:pubmed |
| pubmed-article:20644086 | pubmed:dateCreated | 2010-8-19 | lld:pubmed |
| pubmed-article:20644086 | pubmed:abstractText | PURPOSE We previously reported our results with a single-agent arsenic trioxide (ATO) -based regimen in newly diagnosed cases of acute promyelocytic leukemia (APL). The concern remained about the long-term outcome of this well-tolerated regimen. We report our long-term follow-up data on the same cohort. PATIENTS AND METHODS From January 1998 to December 2004, 72 patients with PML/RARalpha+ APL were enrolled. All patients were treated with a single-agent ATO regimen. Results Overall 62 (86.1%) achieved a hematologic remission (complete remission). After the initial report, an additional seven patients have relapsed for a total of 13 relapses. There were no additional toxicities to report on follow-up. At a median follow-up 60 months, the 5-year Kaplan-Meier estimate (+/- SE) of event-free survival, disease-free survival, and overall survival (OS) was 69% +/- 5.5%, 80% +/- 5.2%, and 74.2% +/- 5.2%, respectively. The OS in the good risk group as defined by us remains 100% over this period. CONCLUSION Single-agent ATO as used in this study in the management of newly diagnosed cases of APL is safe and is associated with durable responses. Results in the low-risk group are comparable to that reported with conventional therapy while additional interventions would probably be required in high-risk cases. | lld:pubmed |
| pubmed-article:20644086 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20644086 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20644086 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20644086 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20644086 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20644086 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20644086 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20644086 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20644086 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20644086 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:GeorgeBijuB | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:SrivastavaAlo... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:MathewsVikram... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:ChandyMammenM | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:Balasubramani... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:ShajiRamachan... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:ViswabandyaAu... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:LakshmiKavith... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:DesireSalamun... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:ChendamaraiEz... | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:AbrahamAbyA | lld:pubmed |
| pubmed-article:20644086 | pubmed:author | pubmed-author:ThirugnanamRa... | lld:pubmed |
| pubmed-article:20644086 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20644086 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:20644086 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:20644086 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20644086 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20644086 | pubmed:pagination | 3866-71 | lld:pubmed |
| pubmed-article:20644086 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:meshHeading | pubmed-meshheading:20644086... | lld:pubmed |
| pubmed-article:20644086 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20644086 | pubmed:articleTitle | Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. | lld:pubmed |
| pubmed-article:20644086 | pubmed:affiliation | Department of Haematology, Christian Medical College and Hospital, Vellore 632004, India; vikram@cmcvellore.ac.in. | lld:pubmed |
| pubmed-article:20644086 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20644086 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20644086 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20644086 | lld:pubmed |
